2.17
price down icon4.82%   -0.11
after-market Dopo l'orario di chiusura: 2.27 0.10 +4.61%
loading
Precedente Chiudi:
$2.28
Aprire:
$2.15
Volume 24 ore:
90,938
Relative Volume:
0.23
Capitalizzazione di mercato:
$228.31M
Reddito:
$7.05M
Utile/perdita netta:
$-30.43M
Rapporto P/E:
-5.7286
EPS:
-0.3788
Flusso di cassa netto:
$21.84M
1 W Prestazione:
-7.66%
1M Prestazione:
+11.28%
6M Prestazione:
+0.00%
1 anno Prestazione:
+15.12%
Intervallo 1D:
Value
$2.13
$2.17
Intervallo di 1 settimana:
Value
$2.13
$2.47
Portata 52W:
Value
$1.07
$4.62

Proqr Therapeutics N V Stock (PRQR) Company Profile

Name
Nome
Proqr Therapeutics N V
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
166
Name
Cinguettio
@proqr
Name
Prossima data di guadagno
2025-03-14
Name
Ultimi documenti SEC
Name
PRQR's Discussions on Twitter

Confronta PRQR con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
PRQR
Proqr Therapeutics N V
2.17 240.18M 7.05M -30.43M 21.84M -0.3788
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-29 Ripresa Cantor Fitzgerald Overweight
2025-04-29 Iniziato Evercore ISI Outperform
2025-03-10 Aggiornamento Citigroup Neutral → Buy
2025-01-10 Iniziato Oppenheimer Outperform
2024-10-29 Aggiornamento Raymond James Outperform → Strong Buy
2023-11-08 Aggiornamento Chardan Capital Markets Neutral → Buy
2023-03-30 Aggiornamento JMP Securities Mkt Perform → Mkt Outperform
2022-12-22 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2022-02-14 Downgrade Citigroup Buy → Neutral
2022-02-11 Downgrade Raymond James Strong Buy → Mkt Perform
2022-02-11 Downgrade Stifel Buy → Hold
2022-02-01 Iniziato Raymond James Strong Buy
2021-05-03 Iniziato Stifel Buy
2021-03-25 Reiterato Citigroup Buy
2020-11-03 Ripresa Cantor Fitzgerald Overweight
2019-03-12 Reiterato Chardan Capital Markets Buy
2018-12-19 Iniziato RBC Capital Mkts Outperform
2018-11-15 Iniziato Citigroup Buy
2018-09-19 Iniziato Evercore ISI Outperform
2017-09-26 Reiterato JMP Securities Mkt Outperform
2016-06-20 Iniziato Chardan Capital Markets Neutral
2014-10-15 Iniziato Deutsche Bank Buy
2014-10-13 Iniziato H.C. Wainwright Buy
Mostra tutto

Proqr Therapeutics N V Borsa (PRQR) Ultime notizie

pulisher
Jul 23, 2025

What drives ProQR Therapeutics N.V. stock priceStrong return on assets - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about ProQR Therapeutics N.V. stockRemarkable growth - printweek.in

Jul 22, 2025
pulisher
Jul 21, 2025

Owning 32% shares,institutional owners seem interested in ProQR Therapeutics N.V. (NASDAQ:PRQR), - Yahoo Finance

Jul 21, 2025
pulisher
Jul 19, 2025

Is ProQR Therapeutics N.V. a good long term investmentFree Stock Selection - Jammu Links News

Jul 19, 2025
pulisher
Jul 19, 2025

ProQR Therapeutics N.V. Stock Analysis and ForecastDynamic investment growth - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Is ProQR Therapeutics N.V. stock a growth or value playTop Momentum Stock Pick - newser.com

Jul 18, 2025
pulisher
Jul 17, 2025

ProQR stock rating reiterated by Cantor Fitzgerald ahead of key 2H25 data - Investing.com Nigeria

Jul 17, 2025
pulisher
Jul 15, 2025

Why ProQR Therapeutics N.V. stock attracts strong analyst attentionFree Stock Selection with 300% Return - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How ProQR Therapeutics N.V. stock performs during market volatilityProven Win Setups - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes ProQR Therapeutics N.V. stock price move sharplyFree Wealth-Building Investment Strategies - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

ProQR Therapeutics N.V.'s (NASDAQ:PRQR) high institutional ownership speaks for itself as stock continues to impress, up 16% over last week - simplywall.st

Jul 15, 2025
pulisher
Jul 14, 2025

ProQR Therapeutics N.V. (NASDAQ:PRQR) Shares Acquired by OneDigital Investment Advisors LLC - Defense World

Jul 14, 2025
pulisher
Jul 11, 2025

ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above Fifty Day Moving AverageWhat's Next? - MarketBeat

Jul 11, 2025
pulisher
Jul 10, 2025

Vontobel Holding Ltd. Invests $48,000 in ProQR Therapeutics N.V. (NASDAQ:PRQR) - Defense World

Jul 10, 2025
pulisher
Jul 07, 2025

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.com Australia

Jul 07, 2025
pulisher
Jul 06, 2025

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles By Investing.com - Investing.com South Africa

Jul 06, 2025
pulisher
Jul 03, 2025

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts - MarketBeat

Jul 03, 2025
pulisher
Jun 30, 2025

ProQR Therapeutics' (PRQR) "Market Outperform" Rating Reaffirmed at JMP Securities - MarketBeat

Jun 30, 2025
pulisher
Jun 28, 2025

ProQR Therapeutics (NASDAQ:PRQR) Given Market Outperform Rating at JMP Securities - Defense World

Jun 28, 2025
pulisher
Jun 27, 2025

PRQR: Cantor Fitzgerald Reiterates Overweight Rating | PRQR Stoc - GuruFocus

Jun 27, 2025
pulisher
Jun 27, 2025

ProQR stock advances as Cantor Fitzgerald reaffirms $8 price target By Investing.com - Investing.com Canada

Jun 27, 2025
pulisher
Jun 27, 2025

ProQR stock advances as Cantor Fitzgerald reaffirms $8 price target - Investing.com

Jun 27, 2025
pulisher
Jun 26, 2025

ProQR submits clinical trial application for RNA editing therapy By Investing.com - Investing.com India

Jun 26, 2025
pulisher
Jun 26, 2025

ProQR Seeks EU Approval for Liver Cell Protein Trial - MarketScreener

Jun 26, 2025
pulisher
Jun 26, 2025

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP - GlobeNewswire

Jun 26, 2025
pulisher
Jun 26, 2025

ProQR Advances First RNA Editing Therapy to Clinical Trials for Liver Disease | PRQR Stock News - Stock Titan

Jun 26, 2025
pulisher
Jun 15, 2025

Bank of America Corp DE Boosts Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World

Jun 15, 2025
pulisher
Jun 13, 2025

ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected - simplywall.st

Jun 13, 2025
pulisher
Jun 13, 2025

Equities Analysts Offer Predictions for PRQR FY2026 Earnings - MarketBeat

Jun 13, 2025
pulisher
Jun 11, 2025

Research Analysts Set Expectations for PRQR FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Jane Street Group LLC Buys Shares of 11,400 ProQR Therapeutics (NASDAQ:PRQR) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Analysts Set ProQR Therapeutics (NASDAQ:PRQR) Target Price at $8.00 - MarketBeat

Jun 09, 2025
pulisher
Jun 09, 2025

ProQR Therapeutics (NASDAQ:PRQR) Shares Sold by Two Sigma Advisers LP - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Squarepoint Ops LLC Grows Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Two Sigma Investments LP Buys 320,614 Shares of ProQR Therapeutics (NASDAQ:PRQR) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of “Buy” by Analysts - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

ProQR Therapeutics (NASDAQ:PRQR) Sees Significant Increase in Short Interest - MarketBeat

Jun 05, 2025
pulisher
Jun 03, 2025

ProQR Shareholders Approve Key Resolutions at Annual Meeting - TipRanks

Jun 03, 2025
pulisher
Jun 02, 2025

ProQR Therapeutics (NASDAQ:PRQR) Shares Purchased by Northern Trust Corp - MarketBeat

Jun 02, 2025

Proqr Therapeutics N V Azioni (PRQR) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Capitalizzazione:     |  Volume (24 ore):